The FDA does not pre-approve dietary supplements before they reach shelves
This umbrella review aimed to determine (1) whether GLP-1 RAs can relieve the development of MASLD and/or lead to safety problems, and (2) which indicators' resolution and/or safety problems were observed with GLP-1 RAs treatment
Severe psychiatric disorders (schizophrenia, paranoid psychosis, bipolar disorder, intellectual disability)
The Billon 2025 paper (PMID 41421047) introduced SLU-PP-915 as an "orally active" sibling specifically because the parent SLU-PP-332 "lacks oral bioavailability." Despite that, the most common vendor formats are oral capsules and tablets products without published evidence that they produce systemic ERR agonism in humans
This design is intended to enhance the formulations tumor-targeting capability and delivery efficiency, thereby achieving synergistic inhibition of both angiogenesis and tumor growth for improved combination therapy of liver cancer [116]
Because standard medicine treats the symptoms